AzurBio Pharma Strengthens Its Foothold in European Regulatory Services with the Acquisition of A-pharmaconsult, Launching AzurBio Consulting.

AzurBio Pharma announces the acquisition of A-pharmaconsult, a well-established European regulatory consultancy with over 30 years of experience in France and across Europe, marking a key milestone in its growth.

This strategic alliance results in the creation of AzurBio Consulting, a brand dedicated to providing European strategic and operational consulting services for pharmaceutical, biotechnology, and medical device companies.

"As President and Founder of AzurBio Pharma, I am delighted to announce this acquisition, which represents a major step forward in our ambition to become a key partner for life sciences companies in Europe. By combining A-pharmaconsult’s recognized expertise with AzurBio Pharma’s innovative and agile approach, we can offer even more effective, tailored solutions to meet our clients’ evolving needs. This strategic alliance allows us to provide customized consulting services and cutting-edge solutions, guiding our partners toward lasting success." said Corinne Schmitz, CEO of AzurBio Pharma, Founder and former CEO of BlueReg and PharmaBlue.

Loïc Girot, Managing Director of A-pharmaconsult, added: "We are excited to join AzurBio Pharma and contribute to the creation of AzurBio Consulting. The synergies we are building will allow us to tackle our clients’ challenges effectively while reinforcing our position as a well-established European consultancy in regulatory affairs and quality management."

About Azurbio Pharma

Headquartered in Paris (France), with offices in Boston (US) and Zug (CH), AzurBio Pharma is a pharmaceutical and service company led by Corinne Schmitz, a recognized entrepreneur in pharmaceutical consulting.
AzurBio Pharma is committed to accelerating access to innovative medicines in Europe, focusing particularly on unmet medical needs, including rare and serious diseases.

AzurBio Pharma's mission is to establish strategic partnerships with biopharmaceutical companies developing promising therapies, offering them turnkey, customized, and innovative solutions to facilitate and accelerate their entry into the European market.